 |
|
The Clinical Risk Score
Emerging as a Reliable Preoperative Prognostic Index in Hepatectomy for Colorectal Metastases
Chris D. Mann, BSc;
Matthew S. Metcalfe, MBBChir;
Lisa N. Leopardi, BEng(Biomed)Hon;
Guy J. Maddern, MD
Arch Surg. 2004;139:1168-1172.
Hypothesis The purpose of this study was to examine the validity of the clinical risk score (CRS), a prognostic tool developed by Fong et al, when translated to another center.
Design This study assesses 5 independent preoperative prognostic criteria, nodal status of the primary lesion, disease-free interval, number of hepatic metastases, size of the largest metastasis, and preoperative carcinoembryonic antigen level, to determine a preoperative CRS for each patient included in the study.
Setting The hepatobiliary unit of The Queen Elizabeth Hospital, Adelaide, South Australia.
Patients Medical records of patients admitted to The Queen Elizabeth Hospital undergoing potentially curative hepatic resection for colorectal metastases during the period of July 1993 to April 2003 were included in the study.
Main Outcome Measure The primary outcome measure of the study was survival. The calculated CRS was analyzed with respect to patient postoperativesurvival.
Results During the 10-year period, 77 patients underwent hepatic resection. Overall survival rates for 1, 3, and 5 years were found to be 80.9%, 57.5%, and 42.3%, respectively. One- and 5-year survival rates for CRSs of 0 and 1 were found to be 93.8% and 72.5%, respectively; for scores of 2 and 3, 76.6% and 31.2%, respectively;and for scores of 4 and 5, 75% and 0%, respectively. No patient with a CRS greater than 3 survived more than2 years.
Conclusion This study validates the CRS, finding it to be highly predictive of patient outcome and survival.
Author Affiliations: University of Adelaide, Department of Surgery, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Improved Long-Term Outcome of Surgery for Advanced Colorectal Liver Metastases: Reasons and Implications for Management on the Basis of a Severity Score
Andres et al.
Ann. Surg. Oncol. 2008;15:134-143.
ABSTRACT
| FULL TEXT
Update of Carcinoembryonic Antigen Radioimmunotherapy with 131I-Labetuzumab After Salvage Resection of Colorectal Liver Metastases: Comparison of Outcome to a Contemporaneous Control Group
Liersch et al.
Ann. Surg. Oncol. 2007;14:2577-2590.
ABSTRACT
| FULL TEXT
Simplified Staging System for Predicting the Prognosis of Patients With Resectable Liver Metastasis: Development and Validation
Minagawa et al.
Arch Surg 2007;142:269-276.
ABSTRACT
| FULL TEXT
Improving Resectability of Hepatic Colorectal Metastases: Expert Consensus Statement
Abdalla et al.
Ann. Surg. Oncol. 2006;13:1271-1280.
FULL TEXT
In Reply:
Liersch et al.
JCO 2006;24:2680-2681.
FULL TEXT
|
